Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine.
Lipton
S A
SA
Chen
H-S V
HS
D003704:Dementia / Q000188:drug therapy*; D016503:Drug Delivery Systems / Q000379:methods; D015195:Drug Design; D006801:Humans; D008559:Memantine / Q000494:pharmacology* / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D008559:Memantine